Calcium 

 132 Products   132 Products   363 Diseases   15997 News 


12345678910111213...216217»
  • ||||||||||  Cardene (nicardipine) / Chiesi
    Enrollment open:  Hypotensive Anesthesia for Orthognathic Surgery (clinicaltrials.gov) -  Apr 1, 2025   
    P4,  N=90, Recruiting, 
    This study demonstrates there is no substantial difference between diluted and undiluted bolus doses of intrathecal ziconotide in regard to analgesic effect or side effects. Not yet recruiting --> Recruiting
  • ||||||||||  senicapoc (ICA-17043) / SpringWorks Therap, UC Davis Health
    Journal:  KCa3.1 Contributes to Neuroinflammation and Nigral Dopaminergic Neurodegeneration in Experimental models of Parkinson's Disease. (Pubmed Central) -  Apr 1, 2025   
    Pharmacological inhibition of KCa3.1 via senicapoc or TRAM-34 inhibits KCa3.1 channel activity and the associated reactive microglial phenotype in response to aggregated ?Syn, as well as ameliorates of PD like pathology in diverse PD mouse models...Moreover, reduced neuroinflammation and subsequent PD-like neuropathology were observed in SYN AAV inoculated KCa3.1 knockout mice. Together, these findings suggest that KCa3.1 inhibition represents a novel therapeutic strategy for treating patients with PD and related ?-synucleinopathies.
  • ||||||||||  Acelex (polmacoxib) / CG Invites, epacadostat (INCB024360) / Incyte, PCI 27483 / AbbVie
    Review, Journal:  Polypharmacology of carbonic anhydrase inhibitors and activators. (Pubmed Central) -  Apr 1, 2025   
    Pathway enrichment analysis (PEA) showed that TMZ is involved in multiple signaling and immune-related pathways that might be, at least partly, implicated in its cytoprotective effects. Several antiepileptics (topiramate, zonisamide, lacosamide, and levetiracetam), some atypical antipsychotics (sulpiride, veralipride), celecoxib, polmacoxib, pazopanib, the antiulcer agent famotidine, and compounds in clinical trials (epacadostat and PCI-27483) as antitumor agents significantly inhibit several CA isoforms of the 15
  • ||||||||||  nifedipine immediate release / Generic mfg.
    Enrollment open, Trial completion date:  Postpartum Hypertension Study (clinicaltrials.gov) -  Apr 1, 2025   
    P4,  N=104, Recruiting, 
    Several antiepileptics (topiramate, zonisamide, lacosamide, and levetiracetam), some atypical antipsychotics (sulpiride, veralipride), celecoxib, polmacoxib, pazopanib, the antiulcer agent famotidine, and compounds in clinical trials (epacadostat and PCI-27483) as antitumor agents significantly inhibit several CA isoforms of the 15 Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> Dec 2027
  • ||||||||||  paclitaxel / Generic mfg., trimetazidine / Generic mfg.
    Trial completion:  Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy (clinicaltrials.gov) -  Mar 31, 2025   
    P1/2,  N=60, Completed, 
    Therefore, this method can not only protect the food safety of large-scale sports events, but also have broad application prospects in the food field. Recruiting --> Completed
  • ||||||||||  Batenac (mibefradil) / Jazz, digoxin / Generic mfg., thioridazine / Generic mfg.
    Journal:  Targeting Ion Channels: Blockers Suppress Calcium Signals and Induce Cytotoxicity Across Medulloblastoma Cell Models. (Pubmed Central) -  Mar 28, 2025   
    However, these effects were significantly diminished in the cells derived from a patient with MB, highlighting the variability in drug sensitivity among MB models. These findings demonstrate that calcium signaling is critical for MB cell survival and that the targeted inhibition of calcium pathways suppresses tumor cell growth across multiple MB models.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Formation of the i-motif Structures by Human Telomeric c-Rich Sequences d(CCCTAA)n and Its Recognition by Bisbenzylisoquinoline Alkaloids. (Pubmed Central) -  Mar 27, 2025   
    Further, telomerase repeated amplification protocol (TRAP) assay suggested that the selected BBI alkaloids can inhibit the telomere extension by telomerase. These findings provide a theoretical basis for further telomere structure research as well as a novel class of natural small molecule compounds regulating the hTelo-iM structure and telomerase activity, which may contribute to the anticancer drug design and strategy development taking the hTelo-iM as a target.
  • ||||||||||  simvastatin / Generic mfg., nimodipine / Generic mfg., quetiapine / Generic mfg.
    Journal:  Crucial role of microglia-mediated myelin sheath damage in vascular dementia: antecedents and consequences. (Pubmed Central) -  Mar 27, 2025   
    Several drugs, including nimodipine, dopaminergic agents, simvastatin, biotin, and quetiapine, have been evaluated for clinical use in treating microglial and myelin damage. Future research will face challenges in developing targeted therapeutic strategies for vascular dementia, requiring further investigation into the timing, duration, and specific mechanisms of microglial activation, as well as the exploration of new drug combinations and additional therapeutic targets.
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Journal:  Development for Probiotics Based Insulin Delivery System. (Pubmed Central) -  Mar 26, 2025   
    We finally confirmed that PP-insulin-CBT1 successfully secreted insulin-CBT1 proteins to culture media. These results presented herein open up new avenues to developing therapeutic options for DM.
  • ||||||||||  verapamil / Generic mfg.
    Journal:  Ameliorating TIMM50 Loss Slows Senescence by Improving Mitochondrial Structure and Function. (Pubmed Central) -  Mar 25, 2025   
    The identification of 16 quality markers provides a scientific reference for quality control in future research. To establish the translational value of the observation, screening several potential anti-aging compounds revealed TIMM50 stabilizing and senescence-delaying effects only for verapamil and mitochondrial ROS
  • ||||||||||  diltiazem / Generic mfg., bleomycin / Generic mfg.
    Preclinical, Journal:  In silico, in vitro, and in vivo assessment of chitosan-diltiazem nanoparticles against pulmonary fibrosis. (Pubmed Central) -  Mar 24, 2025   
    TMC nanoparticles significantly reduced BLM-induced IPF symptoms, i.e. BLM induced increased lung index, hydroxyproline accumulation, oxidative stress in lung tissue, and blood pressure. These findings indicate the strong therapeutic potential of DIL-TMC for IPF with minimal cardiovascular side effects.
  • ||||||||||  trimetazidine / Generic mfg.
    Journal:  Metabolic intervention with trimetazidine improves intracardiac hemodynamics and reduces re-hospitalizations in patients with advanced heart failure. (Pubmed Central) -  Mar 24, 2025   
    Given low prevalence and incidence of hyperkalemia and evident reduction in BP, our study suggests initiating FDC with telmisartan and amlodipine may be a practical and safe option for newly diagnosed hypertension, especially in resource-constrained settings where blood tests cannot be easily obtained. Treatment with trimetazidine 80 mg/daily in addition to standard guideline-based therapy for 6-months decreased hospitalization, improved systolic function and LV filling pressure in advanced HF patients.
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Journal, Adverse events:  Adverse events of dual anti-seizure medication: Real-life data from a tertiary epilepsy clinic. (Pubmed Central) -  Mar 23, 2025   
    While dual ASM therapy is associated with an increased burden of AE, this increase appears to be moderate when therapies are individually tailored. Increased awareness and systematic screening of AE, particularly cognitive side effects, are essential to optimize treatment outcomes.